Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 19, 2026.

Resveratrol: A miraculous natural compound for diseases treatment

Mehdi Koushki, Nasrin Amiri‐Dashatan, Nayebali Ahmadi and 2 more

Food Science & Nutrition · 2018 · Review · CC BY

doi:10.1002/fsn3.855

Abstract

Resveratrol (3, 5, 4′‐trihydroxystilbene) is a nonflavonoid polyphenol that naturally occurs as phytoalexin. It is produced by plant sources such as grapes, apples, blueberries, plums, and peanut. This compound has critical roles in human health and is well known for its diverse biological activities such as antioxidant and anti‐inflammatory properties. Nowadays, due to rising incidence of different diseases such as cancer and diabetes, efforts to find novel and effective disease‐protective agents have led to the identification of plant‐derived compounds such as resveratrol. Furthermore, several in vitro and in vivo studies have revealed the effectiveness of resveratrol in various diseases such as diabetes mellitus, cardiovascular disease, metabolic syndrome, obesity, inflammatory, neurodegenerative, and age‐related diseases. This review presents an overview of currently available studies on preventive properties and essential molecular mechanisms involved in various diseases.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

Resveratrol (RSV) (3, 5, 4′‐trihydroxystilbene) is a phenolic micronutrient compound that is formed naturally by 70 different plant species such as grapes, berries, peanuts, and pines (Harikumar & Aggarwal, 2008; Shishodia & Aggarwal, 2006). The major RSV dietary sources are shown in Figure 1. This metabolite was initially recognized as an antibiotic produced in response to various environmental stresses, such as mechanical damage, microbial infection, UV radiation, heat, and pathogenic conditions (Harikumar & Aggarwal, 2008; Pervaiz, 2003). It was initially extracted from the roots of white hellebore (veratrum grandiflorum O. Loes.) by Michio Takaoka in 1940 (Saiko, Szakmary, Jaeger, & Szekeres, 2008). The plants have varying potential for RSV production. For example, RSV concentration in grapes and peanuts is estimated to be in the range of 0.16–3.54 and 0.02–1.92 μg/g, respectively. The highest levels of RSV are found in Polygonum cuspidatum (524 μg/g; also known as Fallopia japonica, Japanese knotweed), which has been used in traditional Asian medicine for inflammatory treatments (Catalgol, Batirel, Taga, & Ozer, 2012; Kukreja, Wadhwa, & Tiwari, 2013). RSV has a stilbene structure, consisting of two aromatic rings connected by a methylene bridge. Two isomeric forms (cis and Trans) of RSV exist in nature; however, only the trans form of RSV participates in the majority of biological activities because of its stability (Wu & Liu, 2013) (Figure 2). Despite 70% absorption of resveratrol in the body (Walle, 2011), studies performed on rats showed that its bioavailability is relatively low due to its rapid metabolism in the intestine and liver (Goldberg, Yan, & Soleas, 2003). RSV bioavailability exhibits a variability from one person to another that depends on age and gender (Nunes et al., 2009). Bode et al. (2013) reported that RSV metabolism by human gut microbiota shows pronounced interindividual diversity based on the study of health‐related effects of this compound. Several RSV‐derived metabolites also have been reported in the plasma and urine of animals and humans (Azorín‐Ortuño et al., 2011). However, the activity of all these metabolites is not clear. Studies performed on animal models to date have shown no apparent adverse effects of RSV (Johnson et al., 2011; Patel et al., 2010; Rotches‐Ribalta, Andres‐Lacueva, Estruch, Escribano, & Urpi‐Sarda, 2012). The only reported side effect in the studies was the onset of diarrhea after receiving 200 mg of resveratrol daily, which was not associated with clinical complications (la Porte et al., 2010). Overall, adverse effects of RSV have been minor and it appears to have a good safety. RSV causes human platelets aggregation in vitro (Bertelli et al., 1996), therefore recommended not to intake with anticoagulants and antiplatelet drugs (Abu‐Amero, Kondkar, & Chalam, 2016). Nowadays, RSV attracts increasing attention due to naturally occurring compound and the wide range of biological activity and preventive effects on different diseases such as cancers (Gusman, Malonne, & Atassi, 2001; Savouret & Quesne, 2002), neurodegenerative diseases (Chang et al., 2012), cardiovascular disease (Cao & Li, 2004), anti‐inflammatory (Donnelly et al., 2004; Koushki, Dashatan, & Meshkani, 2018), and antioxidant activities (Kawada, Seki, Inoue, & Kuroki, 1998). In addition to RSV, different oligomers (Lins, Ribeiro, Gottlieb, & Gottlieb, 1982) of this compound were found to exhibit broadly biological activities, such as antiviral, anti‐fungal, antibacterial, and anticancer activities (Li, Henry, & Seeram, 2009; Zain, Ahmat, Norizan, & Nazri, 2011). The overall aim of this study was to reveal the potential beneficial effects of resveratrol and its therapeutic mechanisms in various diseases.

Resveratrol as antidiabetic compound

Diabetes mellitus is a metabolic disease, which affects approximately 5% of people worldwide. Type 1 and type 2 are the most common types of diabetes. Diabetes is associated with metabolic abnormalities and long‐term complications such as antipathies, cardiovascular disorders, retinopathy, renal disorder, and neuropathies. On the other hand, despite many attempts in the management of diabetes, current therapeutic methods are accompanied by side effects. Recent investigation indicates that resveratrol is a natural compound exerting numerous beneficial effects on diabetes, which are extensively studied in animal models and in diabetic humans.

Resveratrol and type 1 diabetes

Type 1 diabetes, known as insulin‐dependent diabetes, is a chronic condition that results from the autoimmune destruction of beta cells of the pancreas that produce insulin, a hormone needed to allow sugar (glucose) to enter the cells to produce energy. Only 5%–10% of people with diabetes suffer from this type of disease. Maintaining normoglycemia and preservation of pancreatic β‐cells are the main management aspects in type 1 diabetics (Szkudelski & Szkudelska, 2015). Animal studies clearly confirmed anti‐hyperglycemia effects of RSV and its pancreatic β‐cell protection. The effects of resveratrol in decreasing blood glucose were found in rats with diabetes induced by streptozotocin (STZ) alone and STZ with nicotinamide (NA) (Palsamy & Subramanian, 2010; Silan, 2008). The results of the previous studies have shown that RSV could maintain normoglycemia and protect of pancreatic β‐cells in type 1 diabetics. The normal glucose level in blood is preserved by insulin. Since pancreatic beta cells are the only source of this hormone, it can be concluded that the RSV pancreatic β‐cell protection property is promising. Actually, RSV improves antioxidant capacity in pancreatic beta cells by increasing the antioxidant enzyme content of the cells including superoxide dismutase, catalase, and glutathione S‐transferase. Hereby, pancreatic tissue is protected from the free radical compounds (Palsamy & Subramanian, 2010). In addition, RSV inhibits PARP enzyme cleavage, because of its caspase‐3 enzyme activity blockage and hence decreasing apoptosis of beta cells in STZ‐induced and STAZ‐NA‐induced degeneration of the cells (Figure 3). Protection of beta cells from apoptosis led to blood insulin‐level promotion and decreasing of blood glucose level in type 1 diabetes (Ku et al., 2012). Another main action of RSV compound can be explored in type 1 diabetic skeletal muscle. It was demonstrated that RSV alleviates skeletal muscle dysfunction in type 1 diabetic animal models (Chang et al., 2014; Chen et al., 2011). One of the RSV recovering mechanisms in skeletal muscle pathological conditions is mitochondrial biogenesis stimulation and increasing of lipid metabolism in diabetic models. According to Chen et al. (2011) study, RSV also exerts anti‐inflammatory effects and decrease NF‐κB, IL‐1β, and IL‐6 cytokines. Oxidative stress is another contributing factor to myopathy co‐occurring with inflammation in type 1 diabetes (D'Souza, Al‐Sajee, & Hawke, 2013). Data confirmed the effect of RSV on oxidative stress reduction in skeletal muscle (Chang et al., 2014). It is noteworthy that RSV affects skeletal muscles by increasing GLUT4 expression and augmenting intracellular glucose transport (Deng, Hsieh, Huang, Lu, & Hung, 2008). RSV was also found to reduce gluconeogenesis activity and increase liver glycogenesis, which leads to hepatic glucose output reduction. It should be noted that effects of RSV in the liver are originated from increasing blood insulin level. In addition, RSV alleviated liver tissue abnormalities by hepatoprotective effects (Hamadi, Mansour, Hassan, Khalifi‐Touhami, & Badary, 2012). Overall, the anti‐diabetic effects of resveratrol well established in diabetic animals (Chang et al., 2011, 2014; Hamadi et al., 2012; Ku et al., 2012). Some of the possible mechanisms of resveratrol on type 1 diabetic animal models are shown in Figure 4.

Resveratrol and type 2 diabetes

Type 2 diabetes is the most common form of diabetes. About 90% of all diabetic patients suffer from type 2 diabetes. In these patients, body resists the effects of insulin hormone or shows an insulin secretion deficiency. It is recently established that factors such as inflammation and oxidative stress contribute to worsening of insulin resistance and to β‐cell failure in type 2 diabetics (Hamadi et al., 2012). Besides, insulin resistance in adipocytes, hepatocytes, and muscle cells is still complicating issue. In this context, animal studies provided evidence that RSV as a natural compound has beneficial effects on both mechanisms in these tissues and pancreatic β‐cells (Jiang et al., 2013; Palermo, Maggi, Maurizi, Pozzilli, & Buzzetti, 2014). Although the effects of resveratrol on the inflammatory responses have been investigated in different models, this function of resveratrol in skeletal muscle cells remains unknown. In Sadeghi et al. study, the plausible role of resveratrol in ameliorating palmitate‐induced inflammation in C2C12 skeletal muscle cells investigated. The results of this study indicated that anti‐inflammatory effects of resveratrol are more likely to be a Sirtuin‐1 (SIRT‐1)‐independent mechanism in skeletal muscle cells (Sadeghi, Seyyed Ebrahimi, Golestani, & Meshkani, 2017). The results of several studies confirmed the SIRT‐1 and AMP‐activated protein kinase (AMPK) as the main molecular targets for RSV to protect against pancreatic β‐cell dysfunction and improving insulin sensitivity (Do et al., 2012; Guo et al., 2014). Actually, activation of these targets by RSV as a drug led to cellular and enzymatic phenomena including decreased lipid accumulation, inflammation, and oxidative damage in liver, muscle, and adipocyte tissues and finally led to insulin action improvement in type 2 diabetes (Figure 5). However, another possible mechanism suggested in different studies including increased phosphorylation of insulin receptor, IRS‐1 expression, and phosphorylation of Akt (Chen, Li et al., 2012; Deng et al., 2008). In another in vivo study conducted by Cheng et al., it has been shown that resveratrol promoted nuclear factor erythroid 2‐related factor‐2 (Nrf2) phosphorylation, in the pancreas of methylglyoxal‐treated mice. This finding supports that resveratrol may be useful in the treatment of type 2 diabetes by protecting against pancreatic cell dysfunction (Cheng, Cheng, Lee, Chung, & Chang, 2015). Oxidative stress is also another factor leading to β‐cell failure in type 2 diabetes, and according to animal investigations, RSV decreases the antioxidant damage of β‐cells. Although the exact mechanism of action is not clearly identified, evidences show that this compound is able to improve insulin sensitivity in insulin resistance condition in different animal models. In animal model of type 2 diabetes (db/db mice) with decreased pancreatic β‐cell mass, RSV was found to improve islet function, reduce oxidative stress, and decrease islet destruction and degenerative changes (Do et al., 2012; Lee et al., 2012). Moreover, RSV partially prevents β‐cell failure and increases β‐cell mass. In general, the management of diabetes involves three main aspects: reduction in blood glucose, preservation of beta cells, and, in the case of type 2 diabetes, improvement of insulin action. Data from the literature indicate that the beneficial effects of RSV in relation to diabetes comprise all these aspects.

Resveratrol and cardiovascular diseases

Because of increased incidence of cardiovascular diseases (CVDs) including atherosclerosis, hypertension, stroke, ischemic heart disease, and heart failure, which are the major cause of mortality and morbidity in the world, more investigations are underway in this field (Laslett et al., 2012). Potential cardio‐protective role of RSV against CVDs has also been suggested by studies (Figure 6). Several studies have been shown anti‐atherosclerotic, anti‐hypertensive, anti‐myocardial ischemia, anti‐stroke, and heart failure effects of it. Improvement of bioavailability of nitric oxide (NO) by RSV is one of the cardio‐protective mechanisms of this compound (Leikert et al., 2002). NO contributes to improved vasodilation and decreased platelet aggregation, leukocyte recruitment, and proliferation of smooth muscle cells, which are inhibitors of atherosclerosis formation and progression (Li & Förstermann, 2000). In general, the beneficial effects of RSV via oxygen‐derived radical scavenging or by increasing NO bioavailability in vitro could be promising against CVDs (Frombaum, Le Clanche, Bonnefont‐Rousselot, & Borderie, 2012). In the case of anti‐atherosclerotic effects of RSV, atherosclerosis is now may be considered as an inflammatory disease. Since low‐density lipoproteins (LDLs) involved in atherosclerosis, improvement of lipid profile by RSV, could be an anti‐atherosclerotic potential therapeutic agent. Several preclinical studies have shown that RSV could affect lipid profile significantly via decreasing plasma triglyceride content, LDL cholesterol, and also increasing HDL cholesterol levels (Göçmen, Burgucu, & Gümüşlü, 2011). Cho, Ahn, Kim, Choi, and Ha (2008) reported RSV effects on hypocholesterolemia by down‐regulation of 3‐hydroxyl‐3‐methylglutaryl‐COA reductase enzyme (HMG‐CoA) reductase enzyme in cholesterol biosynthesis processes. On the other hand, also increasing of LDL receptors expression by RSV in hepatocytes under in vitro conditions could led to decreasing of blood LDL cholesterol levels (Yashiro, Nanmoku, Shimizu, Inoue, & Sato, 2012). In addition, RSV decreases LDL oxidation as one of the key events involving in the atherogenesis. Decreasing of LDL oxidation is the result of antioxidant property of RSV, which leads to improvement of lipid metabolism (Witztum & Steinberg, 1991). The cross‐talk between β‐catenin/Wnt and forkhead box O (FOXO) pathways was impaired in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients. In a recent study, Shanaki et al. performed a case–control study in coronary artery disease and demonstrated that RSV treatment could lead to a modest increase in the manganese superoxide dismutase (MnSOD) activity independent of β‐catenin/FOXO pathway. Despite a modest improvement in the β‐catenin/FOXO pathway after RSV treatment, this pathway was not completely repaired in CAD patients (Shanaki et al., 2016). All of these properties suggest that RSV could exert its effects on important factors involved in the atherosclerotic process. It exhibits its beneficial effects on CVDs via multiple functions including activation SIRT‐1, nitric oxide synthase (eNOS), and Nrf2 and decreases tumor necrosis factor‐α (TNF‐α) production (Li, Xia, & Förstermann, 2012). Hypertension is one of main factors for CVDs (Rivera, Morón, Zarzuelo, & Galisteo, 2009), and anti‐hypertensive effects of RSV have been shown in some animal studies (Dolinsky et al., 2013). The mechanism of RSV against hypertension includes endothelium‐dependent pathways (Zordoky, Robertson, & Dyck, 2015). In this mechanism, it increases AMPK, Nrf2, and SIRT‐1 factors, which finally lead to improvement of flow‐mediated vasodilation in animal models (Figure 7). In addition, RSV has effect on myocardial ischemia. Inhibition of platelet aggregation and a potential regeneration of tissue in the infarcted area are some RSV effects on myocardial ischemia (Raj et al., 2014). One of protective mechanisms by RSV in cardiomyocytes is induction of autophagy via SIRT‐1 and AMPK activation and inhibition of fractalkine protein as inhibitor of RSV‐induced autophagy (Xuan et al., 2012). Both antioxidant activity and increasing of nitric oxide bioavailability actions of RSV are required to exert its anti‐ischemic effects (Leikert et al., 2002). Studying of cardiac stem cells demonstrated that RSV could potentiate the regeneration of infarcted myocardium (Gurusamy, Ray, Lekli, & Das, 2010). Recently, several lines of evidences have shown the role of micro‐RNAs (miR‐21, miR‐20b, miR‐27a, miR‐9, miR‐29) in cardio‐protective effects of RSV (Mukhopadhyay, Pacher, & Das, 2011).

Resveratrol and Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disorder and by far the most common cause of dementia. AD is defined by characteristic pathological features such as deposition of amyloid beta (Aβ) peptides and aggregation of hyper‐phosphorylation of tau protein in the form of neurofibrillary tangles (NFTs) (Selkoe, 2001). Aβ is a 39–43 amino acid peptide fragment derived from APP (amyloid precursor protein) processing by beta (β) and gamma (γ)‐secretase enzymes (Huang, Lu, Wo, Wu, & Yang, 2011). Aβ accumulation leads to a characteristic of AD, that is, progressive loss of neurons and neurological decline (Roberson & Mucke, 2006). Numerous studies yet have been underway to discover the potential improving effects of plant extracts in AD under in vivo conditions (Kashani, Tavirani, Talaei, & Salami, 2011;; Soheili, Tavirani, & Salami, 2015). Studies have shown that resveratrol as a natural supplement was involved in various pathophysiologic cycles of AD (Baur & Sinclair, 2006). Antioxidant, anti‐amyloidogenic properties, and beneficial effects of resveratrol against neuro‐inflammation are promising in AD prevention. Oxidative stress by an excessive production of ROS in the brain has been strongly involved in the pathogenesis of AD. Because of low contents of antioxidants, the greater rate of oxygen consumption, and higher content of peroxidation of fatty acids, brain tissue is more susceptible to oxidative stress (Romano, Serviddio, de Matthaeis, Bellanti, & Vendemiale, 2009). Increasing the levels of ROS and reactive nitrogen species can led to protein damage, lipid peroxidation, and finally loss of membrane integrity. All of these events cause injury to neural membranes, cellular damage, and memory impairment (Abolfathi, Mohajeri, Rezaie, & Nazeri, 2012). Numerous studies have indicated that ROS increases Aβ production, which in turn induces oxidative stress, accelerating AD progression (Li, Gong, Dong, & Shi, 2012). Antioxidants have been shown to protect against Aβ‐induced neurotoxicity. RSV as an antioxidant reduces iNOS levels and lipid peroxidation in neuronal cells and increases the production of hem oxygenase‐1 (HO‐1) to weaken oxidative damage to the cells (Ma, Tan, Yu, & Tan, 2014). Also, several in vivo and in vitro studies suggested that activation of astrocytes and microglia affects Aβ accumulation leading to secretion of pro‐inflammatory agents such as cytokines (IL‐6, IL‐1β, TNF‐α) and free radicals. Pro‐inflammatory cytokines in turn induce Aβ aggregation causing ROS and TNF production (Capiralla, Vingtdeux, & Zhao, 2012). RSV decreases pro‐inflammatory mediator's production, clears Aβ aggregation, and relieves oxidative stress and neuron cell death (Saiko et al., 2008). In general, numerous studies show that RSV has intense neuroprotective properties in several models, both in vitro and in vivo (rat models) (Table 1). In addition to its monomers, several oligomers of RSV have been developed and thereby could be used as agents in the treatment of AD (Rivière et al., 2010). In addition, Lu and colleagues designed a novel series of RSV derivatives for AD treatment purposes (Lu et al., 2013). Nevertheless, there is not a complete large‐scale clinical trial until yet.

Resveratrol and Parkinson disease

Parkinson disease (PD) is a chronic and progressive neurodegenerative disease associated with impairment of motor functions (Sun, Wang, Simonyi, & Sun, 2010). It is the second most common neurodegenerative disease and about 2% of people over the age of 65 suffer from the disease (de Rijk et al., 1997). This disease is an autosomal dominant disorder, and mutations in the alpha‐synuclein gene are the cause of this disease. Although environmental and genetic factors contribute to PD development, the exact etiology remains unclear yet (Gasser, 2005; Sun et al., 2010). Recent studies showed that neurotoxic agents are possible inducers of PD such as manganese (Sun, Yang, & Kim, 1993), dimethoxy phenyl‐ethylamine (Koshimura et al., 1997), paraquat (Miller, Sun, & Sun, 2007), and 1‐methyl‐4‐phenyl‐1, 2, 3,6‐tetrahydropyridine (MPTP) causing oxidative stress, and also mitochondrial dysfunction (Alvira et al., 2007) and inflammation are important factors in dopaminergic neurons degeneration in PD (Giasson, Ischiropoulos, Lee, & Trojanowski, 2002; Sun et al., 2010). Mitochondrial dysfunction plays an important role in the pathogenesis of PD. Production of free radicals occurs in complex I inhibition, and then, oxidative stress could lead to PD (Alvira et al., 2007). Several lines of evidence showed the improvement of mitochondrial respiratory capacities by RSV treatment. In fact, RSV activates SIRT1‐AMPK pathway and then induces PGC‐1alpha activity (Ferretta et al., 2014). PGC‐1alpha activation leads to mitochondrial biogenesis and amelioration of its function. Studies in PD experimental models have shown that antioxidant property of RSV protects dopaminergic neurons (Blanchet et al., 2008). Moreover, RSV‐mediated activation and expression of SIRT‐1 reduce alpha‐synuclein aggregation in PD (Donmez et al., 2012). SIRT‐1 deacetylates and activates heat shock factor 1 (HSF1) affecting heat shock protein 70 (HSP70) transcription and the latter can decrease abnormal protein aggregation (Westerheide, 2013). In summary, many environmental factors can activate oxidative pathway, which causes neurodegeneration. On the other hand, RSV has been shown to suppress oxidative pathway (Saiko et al., 2008). Some studies reported synergic effects of RSV to improve age‐related cognitive decline in AD and PD (Sun, Wang, Simonyi, & Sun, 2008). These studies promise new opportunities for therapeutic agents with improved bioavailability for neurodegeneration treatments.

Resveratrol and cancer

Rates of death by cancer are increasing worldwide with an estimated 12 million deaths in 2030 (Society, 2007). The number of death related to cancer will be expected to be doubled each year in the future. Changes in diet and lifestyle are two main environmental factors causing cancer. Recently, the relationship between dietary factors and cancer prevention in different tissues has been investigated. Many compounds have been shown to be efficient for carcinogenesis prevention in animal models and humans as well. Several studies suggest that natural polyphenol compounds have a great effect on cancer protection (Howe et al., 1992). These compounds that are secondary metabolites in plants and polyphenol diet have shown promising against cancer (Lall, Syed, Adhami, Khan, & Mukhtar, 2015). RSV as a polyphenolic compound in plants has a broad protective activity against several types of cancer. Broad in vivo and in vitro investigations have performed in different types of cancer in recent years. PubMed (PubMed Central) was searched with resveratrol and cancer keywords resulted in 2,567 article in this regard. Abundant documents demonstrate the inhibitory effects of RSV on cancer cell growth, cell cycle, and apoptosis. In addition, RSV has the ability to induce differentiation in some cell lines (Wang et al., 2010). Nowadays, there is a growing attention to applying naturally occurring compounds as preventive and therapeutic agents in cancer management. Due to chemo‐resistance and lack of efficiency of common drugs used in cancer treatment, the development of new nature‐derived compounds with high efficiency and low toxicity seems to be essential for management of this dangerous disease (Fresco, Borges, Diniz, & Marques, 2006). There had been a low interest in the therapeutic index of RSV until the 1990s. In 1997, Jang et al. (1997) conducted a study in the field of protective effects of RSV on the skin cancer in mice model of tumorigenesis. After that, many papers published that represent an increasing interest to this compound in the prevention and treatment of cancer and numerous in vitro and in vivo studies were carried out about anticancer properties of natural compounds such as RSV. Results of RSV effects as anticancer agent indicated inhibitory effects of it in three stages of cancer including initiation, progression, and metastasis. In these studies, it was clear that RSV cause cell cycle arrest and finally apoptosis of tumor cells (Dong, 2003). In addition, many of anticancer properties of RSV were related to its antioxidation effects. Resveratrol as an antioxidant agent can lead to DNA damage prevention that is a major cause of tumor formation. RSV‐based chemoprevention and treatment of cancer consist of cellular and molecular mechanisms. One of the anticancer mechanisms of RSV is through induction of apoptosis (Kalra, Roy, Prasad, & Shukla, 2008; Murakami, Matsumoto, Koshimizu, & Ohigashi, 2003; Nakagawa et al., 2001). RSV causes apoptotic effects in various cell lines including JB6, HL‐60 cells, and various human cancer cell lines (Ahmad, Adhami, Afaq, Feyes, & Mukhtar, 2001; Bode & Dong, 2000; Huang, Ma, Goranson, & Dong, 1999; She, Bode, Ma, Chen, & Dong, 2001).

Resveratrol functional mechanisms in cancer prevention

Cancer prevention property of RSV revealed in multiple studies; nevertheless, accurate anticancer mechanisms of RSV remained unknown. Induction of apoptosis is the main approach to cancer prevention as well as therapy. Induction of apoptosis by RSV reported in several in vitro cell culture and in vivo studies. P53 is a tumor‐suppressor gene and plays an critical role in resveratrol‐induced apoptosis (McCarthy, Symonds, & Van Dyke, 1994). However, RSV induces P53‐dependent transcriptional activation (Mahyar‐Roemer, Katsen, Mestres, & Roemer, 2001). In some of the tumor cell lines, it induces apoptosis in a P53‐independent manner (Mahyar‐Roemer et al., 2001). Clément, Hirpara, Chawdhury, and Pervaiz (1998) showed the apoptosis inducing via a CD95‐CD95L pathway in HL‐60 and T47D cells. In addition, RSV makes apoptosis induction through inhibition of mitochondrial ATP synthase. Both of activation of pro‐apoptotic and anti‐apoptotic molecule inhibition by RSV supported in recent studies (Kim, Rhee, Park, & Choi, 2003; Zhou, Chen, Wang, Cai, & Du, 2005). On the other hand, RSV decreases the prostaglandins (PGs) expression by inhibition of COX‐2 enzyme, which catalyzes arachidonic acid conversion into prostaglandins. PGs and NO play important roles in cell proliferation (Sanders, McMichael, & Hendrix, 2000) and angiogenesis (Bertelli et al., 1996), which lead to tumor growth and metastasis. Modulation of detoxifying enzymes (CYPs) (Baur & Sinclair, 2006), inhibition of protein kinase C (PKC) (Subbaramaiah et al., 1998), BCL‐2 (Kalra et al., 2008), and cell cycle regulators (Reagan‐Shaw, Afaq, Aziz, & Ahmad, 2004) are other chemoprevention effects of RSV. Overall, a myriad of studies has shown that several signaling pathways and various RSV targets including CD95 (Gao et al., 2002; Wenzel, Soldo, Erbersdobler, & Somoza, 2005), NF‐κβ (Li et al., 2010), Wnt (Parekh, Motiwale, Naik, & Rao, 2011), SIRT‐1, and PI3K/AKt (Kucharczak, Simmons, Fan, & Gélinas, 2003) involved in RSV‐induced anticancer effects. Tumor infraction and angiogenesis suppression are strategies against cancer spreading. Investigations suggest that RSV may act as an anticancer agent to inhibit angiogenesis through affecting hypoxia‐inducible factor‐1 alpha (HIF‐1α) and vascular endothelial growth factor (VEGF) in different cancer cells in vitro (Garvin, Öllinger, & Dabrosin, 2006; Zhang et al., 2005). Park et al. (2007) reported RSV‐mediated debilitation of LPA‐induce pathways of tumor migration in ovarian cancer cells. Diminishing of matrix metalloproteinase expression by RSV and concomitant inhibition of diverse cancer cells invasions concluded in several studies. In addition, RSV oligomers and derivatives have important biological actions in cancer prevention (Li et al., 2009). Figure 8)

Resveratrol and kidney disease

Kidney disorders usually occur due to oxidative stress and inflammation. Polycystic kidney disease (PKD) is an autosomal dominant kidney disorder (Wilson & Goilav, 2007) with mutations in polycystin‐1 (PC1) and polycystin‐2 (PC2) encoding genes (i.e., PKD1 and PKD2). These mutations are initiator cysts formation and progression of disease (Zoja et al., 2014). Some of the pro‐inflammatory factors are identified in cyst fluid or urine samples of PKD patients (Ta, Harris, & Rangan, 2013). Recently, it has been shown that inflammation and cytokine signaling play a significant role in PKD pathogenesis. For example, high concentrations of inflammatory factors (chemokines and cytokines) have been shown by Gardner et al. in kidney patients (Swenson‐Fields et al., 2013). Anti‐inflammatory and antioxidant properties of RSV by inducing antioxidant enzymes production (Spanier et al., 2009) and modulating nuclear factors involved in the inflammation‐oxidative stress cycle (Palsamy & Subramanian, 2011) and established in numerous studies; therefore, it can act as a novel therapeutic agent in kidney disease treatments (Kim, Cha, & Surh, 2010). Wu et al. (2016) demonstrated that RSV acts as an anti‐inflammatory substance, which delayed PKD progression through attenuation of NF‐κB‐induced inflammation. CKD, also known as chronic renal disease, is a progressive loss of kidney function. Of CKD’s risk factors, inflammation and oxidative stress are most important (Stenvinkel, 2010). Given that inflammation and oxidative stress are related to CKD pathogenesis, RSV attracted specific interest in its treatment. In 2013, Liang et al. suggested that resveratrol inhibits oxidative stress and renal interstitial fibrosis in mice (Liang, Tian, Han, & Xiong, 2014). In addition, polyphenol supplementation showed that antioxidant activity and lipid profile improvements in hemodialysis patients (Castilla et al., 2008; Yiu, Chen, Chang, Chiu, & Lin, 2010). However, no study has been developed to investigate resveratrol effects in CKD patients, although beneficial effects of RSV could be hopeful in these patients (Figure 9) (Saldanha, Leal Vde, Stenvinkel, Carraro‐Eduardo, & Mafra, 2013).

Hepatic effects of resveratrol

Liver disorders include several maladies such as inborn metabolic disease, alcoholic cirrhosis, viral hepatitis, and drug‐induced hepatotoxicity. The liver disease remains a major cause of morbidity and mortality with significant economic and social costs. Several novel approaches are currently being studied which may provide a better therapeutic outcome for sufferers. The use of naturally occurring polyphenols, some of them obtained from the dietary sources, in the amelioration of illnesses have recently gained considerable popularity (Bishayee, Darvesh, Politis, & McGory, 2010). These agents, having antioxidant and anti‐inflammatory properties, provide a safe and effective means of ameliorating chronic diseases. RSV, a grape polyphenol, has shown a considerable promise as a therapeutic agent in the treatment of the aforementioned liver ailments (Bishayee et al., 2010). The use of RSV supplements with therapeutic and protective potential has investigated in hepatic disease models. Several preclinical and clinical studies have demonstrated the therapeutic usefulness of RSV in several chronic illnesses such as arthritis, diabetes, neoplastic, and neurodegenerative diseases (Saiko et al., 2008). Recently, the studies have shown that RSV has much therapeutic potential on liver disorders. RSV significantly decreased lipid accumulation and apoptosis and provided liver protection against chemical and alcohol‐induced injury. It is able to improve glucose metabolism and lipid profile and decrease liver steatosis. RSV improved hepatic lipid accumulation and progression of nonalcoholic steatohepatitis through down‐regulation of inflammatory signaling pathways (Ji, Wang, Deng, Li, & Jiang, 2015). In a recent study, it was found that mice fed with a methionine–choline‐deficient diet and receive daily intra‐gastric administration of RSV (100 or 250 mg/kg body weight) resulted in reduction of hepatic steatosis and inflammation, while the curative effects of RSV were not seen in the improvement of steatohepatitis (Heebøll et al., 2015). In another study, the findings have shown that daily consumption of RSV with a dose of 500 mg for 12 weeks improved nonalcoholic fatty liver disease in a clinical trial (Faghihzadeh, Adibi, Rafiei, & Hekmatdoost, 2014). The bases for the beneficial effects of RSV are unclear yet. RSV has direct antioxidant effects but also stimulates the expression of antioxidant enzymes and the activity of SIRT‐1 and adenosine monophosphate AMPK both of which have major effects on glucose and fat metabolism and may play a role in aging.

Glaucoma

Glaucoma is a multifactorial neurodegenerative ocular disease which characterized by progressive apoptosis of retinal ganglion cells (RGCs) (Abu‐Amero et al., 2016; Foster, Buhrmann, Quigley, & Johnson, 2002). Oxidative stress (Tezel, 2006) and mitochondrial dysfunction (Kong, Van Bergen, Trounce, & Crowston, 2009) are damaging factors in glaucoma, and underlying mechanisms are under investigation still. Progressive loss of RGCs leads to increasing level of IOP (Abu‐Amero et al., 2016). Yet devaluation of IOP is impressive procedure to treat the disease, and other ways such as laser trabeculoplasty and surgery may be used to slow the disease progression. Efforts to introduce novel potential drug targets are in focus of research. Luna et al. studied RSV effects on glaucoma markers in trabecular meshwork cells. In this study, the authors reported decreased production of iROS and inflammatory factors (IL‐1α, IL‐6, IL‐8, and ELAM‐1) (Luna et al., 2009). The results of the recent studies have shown the antioxidant potency of RSV in trabecular meshwork cells. It is believed that neuroprotective drug from RGCs against apoptosis could be an effective way in the management of glaucoma. Pirhan et al. (2016) studied the effects of RSV and riluzole on the survival of RGCs in rats. They concluded that combined therapy results in high RGCs protection. The detailed molecular mechanisms underlying riluzole and RSV neuroprotective effects are not clear. Another study using young–adult Thy1‐yellow fluorescent protein (YFP) and C57BL mice confirmed previous study observations which referred based on dendrite RGCs protection role of RSV (Pirhan et al., 2016). Razali and colleagues performed reduction in IOP using the topical use of trans‐resveratrol induced in SIOH rat models. The study suggested that repeated topical use of trans‐resveratrol during 21 days in SIOH rat; maintained IOP reduction, which was related to increasing of aqueous MMP‐2; improvement of retinal morphology; and amendment of the retinal condition (Razali et al., 2015). In addition, trans‐resveratrol‐induced IOP reduction also is important in POAG eyes (Clark & Wordinger, 2009); though, these results need to be certified in human studies. One of the factors that contribute to glaucoma pathogenesis is the role of mitochondrial dysfunction. In this regard, Chen and colleagues evaluated RSV‐induced mitochondrial biogenesis in retinal ganglion cell line RGC‐5. In this study, the authors have shown evidence about the role of RSV to attenuate serum deprivation‐induced elicited RGC‐5 cell death through the SIRT‐1‐dependent PGC‐1α subcellular translocation; therefore, they suggested promoting mitochondrial biogenesis in order to mitigate glaucomatous retinopathy (Liu et al., 2013).

Diabetic retinopathy

Diabetic retinopathy, the most common diabetic eye disease, occurs when the blood vessels of retina change. Sometimes, these vessels swell and leak fluid or even close off completely. In other cases, abnormal new blood vessels grow on the surface of the retina. RSV supplementation has recently been studied in diabetic rat models (Soufi, Mohammad‐Nejad, & Ahmadieh, 2012). In this study, the supplemented rats were compared with diabetic and non‐diabetic controls. Authors reported that resveratrol‐induced suppression of eNOS in the eyes of diabetic rats. eNOS is related to inflammation in chronic diabetes and vascular neovascularization (Yar et al., 2012). Evaluation of the RSV effects on vascular damage and induction of VEGF in the retinas of mice with induced diabetes have shown that increasing of vessel leakage and VEGF protein levels are prevented by RSV treatment (Kim, Kim, Roh, Choi, & Cho, 2012). Li, Wang, Huang, and Zheng (2012) have shown that RSV has inhibition effects on endoplasmic reticulum stress (ERS), which is related to retinal vascular degeneration. In another study, the ability of RSV to inhibit RPE cell inflammation caused by hyperglycemia in vitro was evaluated and inhibition of VEGF, TGF‐β1, COX‐2, IL‐6, and IL‐8 accumulations was observed in a dose‐dependent manner in the treated cells with RSV. In addition, PKCB activity reduction was reported in the presence of RSV (Losso, Truax, & Richard, 2010).

Cataract

Cataract is the clouding of the lens of one or both eyes leading to a decrease in vision. Symptoms may include faded colors, blurry vision, and halos around light, trouble with bright lights, and trouble seeing at night. Cataracts are the cause of half of blindness and 33% of visual impairment worldwide. Cataract is most commonly due to aging, but it may also occur due to trauma or radiation exposure and be present from birth. Risk factors include diabetes, smoking tobacco, prolonged exposure to sunlight, and alcohol. Either clumps of protein or yellow‐brown pigment may be deposited in the lens reducing the transmission of light to the retina at the back of the eye. Age‐related cataract is related to prolonged oxidative stress. This condition is a major cause of blindness in emerging countries (Bola, Bartlett, & Eperjesi, 2014). Cataract rat models created using sodium selenite. Doganay, Borazan, Iraz, and Cigremis (2006) established the RSV role in selenite‐induced cataract preventions. The study reported that RSV treatment leads to increasing levels of reduced glutathione (GSH) in rat lenses and erythrocytes (Doganay et al., 2006). High levels of GSH cause protection against oxidant damaging in lens (Hightower & McCready, 1991). In addition, malondialdehyde (MDA) as a lipid peroxidation marker decreased in a resveratrol‐treated rat. These studies have shown the potential potency of RSV in the selenite‐induced cataract formation (Doganay et al., 2006). Recently, Wang et al. evaluated protective effects of RSV on lens epithelial cell apoptosis in diabetic cataract rats. In this study, a rat model of diabetic retinopathy created by intraperitoneal injection of STZ. The results indicated that RSV could control the progression of cataract in diabetic rat efficiently in a dose‐dependent manner, using caspase‐3 expression level apoptosis ratio as an apoptotic index. The outcomes showed the protective effects of RSV on epithelial cell apoptosis prevention in a dose‐dependent manner in diabetic cataract rat lens. It is noteworthy that regulatory mechanisms of RSV in lens epithelial cell (LEC) is unclear and need to be investigated in more detail. Overall, RSV has the potential to play a role in the treatment of a range of retinal conditions and further clinical trials need to determine the RSV effectiveness as an ocular nutrition supplement.

Antimicrobial and antiviral effects of resveratrol

Antiviral effects of RSV have been investigated in several human and animal viruses including influenza A virus (Palamara et al., 2005), Epstein‐Bar virus (Chen, Qiao et al., 2012), herpes simplex virus (Chen, Qiao et al., 2012), HIV (Clouser et al., 2012), and hepatitis C virus (Nakamura et al., 2010). Results from most of these studies indicate that RSV can prevent inhibiting protein synthesis and thus inhibit virus proliferation (Yang et al., 2015). In summary, in spite of inhibiting protein synthesis, other major mechanisms of RSV against viral infections include the following: (a) signaling pathway inhibition and (b) inhibition of gene expression. In 2015, Mora‐Pale et al. examined the antimicrobial activity of two isomers including resveratrol–trans‐dihydrodimer and Pallidol (enzymatic oligomerization of plant polyphenol RSV in vitro). Authors observed the antimicrobial activity of resveratrol–trans‐dihydrodimer against Gram‐positive bacteria (Bacillus cereas, Listeria monocytogenes, Staphylococcus aureas) and against Gram‐negative Escherichia coli with minimal mammalian cells (HepG2 cell line) cytotoxicity. In this study, Pallidol had no antimicrobial activity against all above‐mentioned strains. However, authors performed transcriptomic analysis and detected decreasing expression of ABC transporters, genes related to cell division and DNA binding proteins. In addition, flow‐cytometric analysis of treated cells implied membrane potential disruption and DNA synthesis inhibition through blocking of DNA gyrase activity. According to the literature, RSV exhibits the most potent inhibitory activity on Helicobacter pylori infection under natural condition (Murano et al., 2005). Chan (2002) evaluated the antimicrobial activity of RSV against bacteria and dermatophytes as skin infection agents and indicated the anti‐fungal effects of RSV. However, the author suggested that resveratrol may have also potential novel applications in diabetic wounds treatment. Hwang and Lim (2015) have shown an antibacterial activity of RSV against E. coli and suggested that RSV exerts anti‐E. coli activity through suppression of ftsZ expression (an essential cell division protein in prokaryotes) and Z‐ring formation (contractile ring in bacterial cell division).

Leishmanicidal effects of resveratrol

Leishmaniasis is a neglected disease and a public health problem that affects 98 countries. Over 350 million people are at risk, and approximately 0.9–1.2 million new cases of leishmaniasis occurs per year (Alvar et al., 2012). During blood feeding by female sandflies, metacyclic promastigotes are regurgitated. These promastigotes are then phagocytosed by cells at the site of the bite. Once inside the host cells, metacyclic promastigotes transform into amastigotes, which can survive and replicate inside phagolysosomes (Veras & Bezerra de Menezes, 2016). The first‐line drugs for leishmaniasis are pentavalent antimonials. Alternative treatments are amphotericin B, pentamidine, and paramomycin. All of these drugs have high toxicity, low efficiency, side effects, and high costs (Barrett & Croft, 2012; Berman, 2003). For these reasons, the search for new drugs discovery is required for leishmaniasis management. Recently, several natural compounds attracted interest of scientists in leishmaniasis. There are only very few studies about leishmanicidal effects (each of leishmanial species) of RSV and its analogs (four study). First time, Kedzierski et al. investigated resveratrol and it is hydroxylated (3,4,4′,5‐tetrahydroxy‐trans‐stilbene) analog for the cause of cutaneous lesion (leishmania major), which the findings of its study indicated antileishmanial effects of RSV on extracellular (promastigotes) and intracellular (amastigotes) forms and also the analogs of RSV only affected the promastigote form (Kedzierski, Curtis, Kaminska, Jodynis‐Liebert, & Murias, 2007). Nevertheless, previous study (Kedzierski et al., 2007) for antileishmanial effects of RSV, Lucas and Kolodziej (2013), has shown RSV antipromastigotes activity at 153.2 μM, inhibition effect on NO production, and induction of apoptosis in noninfected macrophages. In addition, the results demonstrated that antileishmanial activity of RSV was due to cytotoxic effects on host cells not because of its antiparasitic properties. In addition, Cytotoxic effects of RSV on noninfected J774‐G8 and BMMΦ cells have been shown using FASC analysis, MTT assay, and microscopic evaluation also have been shown, although authors mention that J774‐G8 is a cancer cell line and cytotoxic effect of RSV on this cell line may be arising from chemoprotective properties of RSV (Lucas & Kolodziej, 2013). Furthermore, other studies in human models need to be evaluated. Ferreira et al. studied the effects of RSV and RSV + AMB against leishmania amazonesis, and they indicated the antipromastigote (IC50 =27 μM) and antiamastigote (IC50 = 42 μM) effects of RSV. RSV with AMB showed synergism for amastigotes of this Leishmania species. Cell cycle analysis showed that RSV increased promastigotes in G0/G1 phase, reduced mitochondrial potential, and elevated choline peak and CH2‐to‐CH3 ratio in NMR technique (Ferreira et al., 2014). All of these results indicate which parasite dies under study condition. In recent year, leishmanicidal effect of four synthetic trans‐resveratrol analogs has performed (Passos, Ferreira, Soares, & Saraiva, 2015). The most important result of this study was that piceatannol analog was the more promising agent for the treatment of leishmaniasis. Complete results of this study are shown in Table 2. All of these studies suggested the RSV and RSV with AMB could be a novel potential therapy in leishmaniosis control and merit further investigation in future.

CONCLUSION

Natural compounds for prevention and treatment of different diseases especially cancer and chronic diseases attracted more interest in recent years. Resveratrol is a natural polyphenol that is present in different human dietary sources. Investigations have shown that resveratrol supplementation has many beneficial effects for prevention and treatment of a variety of diseases with different pathophysiological mechanisms. A wide range of studies pertaining to beneficial effects of resveratrol is conducted in vitro and animal model experiments. It has the capacity to interact with several molecular targets and has been found non‐toxic in these models. On the other hand, these trials must be conducted with optimization of resveratrol bioavailability, dosage, and safety profile in a different population. Yet, there are limited clinical trials and extensive human studies with large sample size are needed in order to determine the potential effects of resveratrol for therapeutic use from bench to bed.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

No animals/humans were used for studies that are the basis of this review.

References 178

  1. 1.

    Abolfathi, A. A., Mohajeri, D., Rezaie, A., & Nazeri, M. (2012 ). Protective effects of green tea extract against hepatic tissue injury in streptozotocin‐induced diabetic rats. Evidence‐Based Complementary and Alternative Medicine, 2012, 740671.

    Not in our library10.1155/2012/740671

  2. 2.
  3. 3.

    Ahmad, N., Adhami, V. M., Afaq, F., Feyes, D. K., & Mukhtar, H. (2001 ). Resveratrol causes WAF‐1/p21‐mediated G1‐phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clinical Cancer Research, 7(5), 1466–1473.

    Not in our library

  4. 4.
  5. 5.

    Alvira, D., Yeste‐Velasco, M., Folch, J., Verdaguer, E., Canudas, A. M., Pallàs, M., & Camins, A. (2007 ). Comparative analysis of the effects of resveratrol in two apoptotic models: Inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience, 147(3), 746–756.

    Not in our library10.1016/j.neuroscience.2007.04.029

  6. 6.

    Azorín‐Ortuño, M., Yáñez‐Gascón, M. J., Vallejo, F., Pallarés, F. J., Larrosa, M., Lucas, R., … Espín, J. C. (2011 ). Metabolites and tissue distribution of resveratrol in the pig. Molecular Nutrition and Food Research, 55(8), 1154–1168.

    Not in our library10.1002/mnfr.201100140

  7. 7.

    Barrett, M. P., & Croft, S. L. (2012 ). Management of trypanosomiasis and leishmaniasis. British Medical Bulletin, 104, 175–196.

    Not in our library10.1093/bmb/lds031

  8. 8.

    Baur, J. A., & Sinclair, D. A. (2006 ). Therapeutic potential of resveratrol: The in vivo evidence. Nature Reviews Drug Discovery, 5(6), 493–506.

    Not in our library10.1038/nrd2060

  9. 9.

    Berman, J. (2003 ). Current treatment approaches to leishmaniasis. Current Opinion in Infectious Diseases, 16(5), 397–401.

    Not in our library10.1097/00001432-200310000-00005

  10. 10.

    Bertelli, A., Giovannini, L., Stradi, R., Urien, S., Tillement, J. P., & Bertelli, A. (1996 ). Kinetics of trans‐and cis‐resveratrol (3,4’,5‐trihydroxystilbene) after red wine oral administration in rats. International Journal of Clinical Pharmacology Research, 16(4–5), 77–81.

    Not in our library

  11. 11.

    Bishayee, A., Darvesh, A. S., Politis, T., & McGory, R. (2010 ). Resveratrol and liver disease: From bench to bedside and community. Liver International, 30(8), 1103–1114.

    Not in our library10.1111/j.1478-3231.2010.02295.x

  12. 12.

    Blanchet, J., Longpré, F., Bureau, G., Morissette, M., DiPaolo, T., Bronchti, G., & Martinoli, M. G. (2008 ). Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP‐treated mice. Progress in Neuro‐Psychopharmacology and Biological Psychiatry, 32(5), 1243–1250.

    Not in our library10.1016/j.pnpbp.2008.03.024

  13. 13.

    Bode, L. M., Bunzel, D., Huch, M., Cho, G. S., Ruhland, D., Bunzel, M., … Kulling, S. E. (2013 ). In vivo and in vitro metabolism of trans‐resveratrol by human gut microbiota. The American Journal of Clinical Nutrition, 97(2), 295–309.

    Not in our library10.3945/ajcn.112.049379

  14. 14.

    Bode, A. M., & Dong, Z. (2000 ). Signal transduction pathways: Targets for chemoprevention of skin cancer. The Lancet Oncology, 1(3), 181–188.

    Not in our library10.1016/s1470-2045(00)00029-2

  15. 15.

    Bola, C., Bartlett, H., & Eperjesi, F. (2014 ). Resveratrol and the eye: Activity and molecular mechanisms. Graefe's Archive for Clinical and Experimental Ophthalmology, 252(5), 699–713.

    Not in our library10.1007/s00417-014-2604-8

  16. 16.

    Cao, Z., Fang, J., Xia, C., Shi, X., & Jiang, B. H. (2004 ). trans‐3, 4, 5′‐Trihydroxystibene inhibits hypoxia‐inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clinical Cancer Research, 10(15), 5253–5263.

    Not in our library10.1158/1078-0432.ccr-03-0588

  17. 17.

    Cao, Z., & Li, Y. (2004 ). Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: Protection against oxidative and electrophilic injury. European Journal of Pharmacology, 489(1), 39–48.

    Not in our library10.1016/j.ejphar.2004.02.031

  18. 18.

    Capiralla, H., Vingtdeux, V., Venkatesh, J., Dreses‐Werringloer, U., Zhao, H., Davies, P., … Marambaud, P. (2012 ). Identification of potent small‐molecule inhibitors of STAT3 with anti‐inflammatory properties in RAW 264.7 macrophages. The FEBS Journal, 279(20), 3791–3799.

    Not in our library10.1111/j.1742-4658.2012.08739.x

  19. 19.

    Capiralla, H., Vingtdeux, V., Zhao, H., Sankowski, R., Al‐Abed, Y., Davies, P., … Marambaud, P. (2012 ). Resveratrol mitigates lipopolysaccharide‐and Aβ‐mediated microglial inflammation by inhibiting the TLR4/NF‐κB/STAT signaling cascade. Journal of Neurochemistry, 120(3), 461–472.

    Not in our library10.1111/j.1471-4159.2011.07594.x

  20. 20.

    Castilla, P., Dávalos, A., Teruel, J. L., Cerrato, F., Fernández‐Lucas, M., Merino, J. L., … Lasunción, M. A. (2008 ). Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. The American Journal of Clinical Nutrition, 87(4), 1053–1061.

    Not in our library10.1093/ajcn/87.4.1053

  21. 21.
  22. 22.

    Chan, M. M.‐Y. (2002 ). Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochemical Pharmacology, 63(2), 99–104.

    Not in our library10.1016/s0006-2952(01)00886-3

  23. 23.

    Chang, C.‐C., Chang, C. Y., Wu, Y. T., Huang, J. P., Yen, T. H., & Hung, L. M. (2011 ). Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP‐activated protein kinase. Journal of Biomedical Science, 18(1), 47

    Not in our library10.1186/1423-0127-18-47

  24. 24.

    Chang, J., Rimando, A., Pallas, M., Camins, A., Porquet, D., Reeves, J., … Casadesus, G. (2012 ). Low‐dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiology of Aging, 33(9), 2062–2071.

    Not in our library10.1016/j.neurobiolaging.2011.08.015

  25. 25.

    Chang, C. C., Yang, M. H., Tung, H. C., Chang, C. Y., Tsai, Y. L., Huang, J. P., … Hung, L. M. (2014 ). Resveratrol exhibits differential protective effects on fast‐and slow‐twitch muscles in streptozotocin‐induced diabetic rats. Journal of Diabetes, 6(1), 60–67.

    Not in our library10.1111/1753-0407.12072

  26. 26.

    Chen, K.‐H., Cheng, M. L., Jing, Y. H., Chiu, D. T., Shiao, M. S., & Chen, J. K. (2011 ). Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin‐induced diabetic rats. American Journal of Physiology‐Endocrinology and Metabolism, 301(5), E853–E863.

    Not in our library10.1152/ajpendo.00048.2011

  27. 27.

    Chen, S., Li, J., Zhang, Z., Li, W., Sun, Y., Zhang, Q., … Zhu, W. (2012 ). Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Canadian Journal of Physiology and Pharmacology, 90(2), 237–242.

    Not in our library10.1139/y11-123

  28. 28.

    Chen, X., Qiao, H., Liu, T., Yang, Z., Xu, L., Xu, Y., … Li, E. (2012 ). Inhibition of herpes simplex virus infection by oligomeric stilbenoids through ROS generation. Antiviral Research, 95(1), 30–36.

    Not in our library10.1016/j.antiviral.2012.05.001

  29. 29.

    Cheng, A.‐S., Cheng, Y. H., Lee, C. Y., Chung, C. Y., & Chang, W. C. (2015 ). Resveratrol protects against methylglyoxal‐induced hyperglycemia and pancreatic damage in vivo. Nutrients, 7(4), 2850–2865.

    Not in our library10.3390/nu7042850

  30. 30.

    Cho, I. J., Ahn, J. Y., Kim, S., Choi, M. S., & Ha, T. Y. (2008 ). Resveratrol attenuates the expression of HMG‐CoA reductase mRNA in hamsters. Biochemical and Biophysical Research Communications, 367(1), 190–194.

    Not in our library10.1016/j.bbrc.2007.12.140

  31. 31.

    Clark, A. F., & Wordinger, R. J. (2009 ). The role of steroids in outflow resistance. Experimental Eye Research, 88(4), 752–759.

    Not in our library10.1016/j.exer.2008.10.004

  32. 32.

    Clément, M.‐V., Hirpara, J. L., Chawdhury, S. H., & Pervaiz, S. (1998 ). Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling‐dependent apoptosis in human tumor cells. Blood, 92(3), 996–1002.

    Not in our library

  33. 33.

    Clouser, C. L., Chauhan, J., Bess, M. A., van Oploo, J. L., Zhou, D., Dimick‐Gray, S., … Patterson, S. E. (2012 ). Anti‐HIV‐1 activity of resveratrol derivatives and synergistic inhibition of HIV‐1 by the combination of resveratrol and decitabine. Bioorganic and Medicinal Chemistry Letters, 22(21), 6642–6646.

    Not in our library10.1016/j.bmcl.2012.08.108

  34. 34.

    Cristòfol, R., Porquet, D., Corpas, R., Coto‐Montes, A., Serret, J., Camins, A.,... Sanfeliu, C. (2012 ). Neurons from senescence‐accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. Journal of Pineal Research, 52(3), 271–281.

    Not in our library10.1111/j.1600-079x.2011.00939.x

  35. 35.

    Deng, J.‐Y., Hsieh, P. S., Huang, J. P., Lu, L. S., & Hung, L. M. (2008 ). Activation of estrogen receptor is crucial for resveratrol‐stimulating muscular glucose uptake via both insulin‐dependent and‐independent pathways. Diabetes, 57(7), 1814–1823.

    Not in our library10.2337/db07-1750

  36. 36.

    de Rijk, M. D., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez‐Pousa, S., … Rocca, W. A. (1997 ). Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 62(1), 10–15.

    Not in our library10.1136/jnnp.62.1.10

  37. 37.

    Do, G. M., Jung, U. J., Park, H. J., Kwon, E. Y., Jeon, S. M., McGregor, R. A., & Choi, M. S. (2012 ). Resveratrol ameliorates diabetes‐related metabolic changes via activation of AMP‐activated protein kinase and its downstream targets in db/db mice. Molecular Nutrition and Food Research, 56(8), 1282–1291.

    Not in our library10.1002/mnfr.201200067

  38. 38.

    Doganay, S., Borazan, M., Iraz, M., & Cigremis, Y. (2006 ). The effect of resveratrol in experimental cataract model formed by sodium selenite. Current Eye Research, 31(2), 147–153.

    Not in our library10.1080/02713680500514685

  39. 39.

    Dolinsky, V. W., Chakrabarti, S., Pereira, T. J., Oka, T., Levasseur, J., Beker, D., … Dyck, J. R. (2013 ). Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochimica et Biophysica Acta (BBA)‐Molecular Basis of Disease, 1832(10), 1723–1733.

    Not in our library10.1016/j.bbadis.2013.05.018

  40. 40.

    Dong, Z. (2003 ). Molecular mechanism of the chemopreventive effect of resveratrol. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 523, 145–150.

    Not in our library10.1016/s0027-5107(02)00330-5

  41. 41.

    Donmez, G., Arun, A., Chung, C. Y., McLean, P. J., Lindquist, S., & Guarente, L. (2012 ). SIRT1 protects against α‐synuclein aggregation by activating molecular chaperones. The Journal of Neuroscience, 32(1), 124–132.

    Not in our library10.1523/jneurosci.3442-11.2012

  42. 42.

    Donnelly, L. E., Newton, R., Kennedy, G. E., Fenwick, P. S., Leung, R. H., Ito, K., … Barnes, P. J. (2004 ). Anti‐inflammatory effects of resveratrol in lung epithelial cells: Molecular mechanisms. American Journal of Physiology‐Lung Cellular and Molecular Physiology, 287(4), L774–L783.

    Not in our library10.1152/ajplung.00110.2004

  43. 43.
  44. 44.

    Faghihzadeh, F., Adibi, P., Rafiei, R., & Hekmatdoost, A. (2014 ). Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutrition Research, 34(10), 837–843.

    Not in our library10.1016/j.nutres.2014.09.005

  45. 45.
  46. 46.

    Ferreira, C., Soares, D. C., do Nascimento, M. T. C., Pinto‐da‐Silva, L. H., Sarzedas, C. G., Tinoco, L. W., … Saraiva, E. M. (2014 ). Resveratrol is active against Leishmania amazonensis: In vitro effect of its association with amphotericin B. Antimicrobial agents and chemotherapy, AAC, 58(10), 6197–6208.

    Not in our library10.1128/aac.00093-14

  47. 47.

    Ferretta, A., Gaballo, A., Tanzarella, P., Piccoli, C., Capitanio, N., Nico, B., … Cocco, T. (2014 ). Effect of resveratrol on mitochondrial function: Implications in parkin‐associated familiar Parkinson's disease. Biochimica et Biophysica Acta (BBA)‐Molecular Basis of Disease, 1842(7), 902–915.

    Not in our library10.1016/j.bbadis.2014.02.010

  48. 48.

    Foster, P. J., Buhrmann, R., Quigley, H. A., & Johnson, G. J. (2002 ). The definition and classification of glaucoma in prevalence surveys. British Journal of Ophthalmology, 86(2), 238–242.

    Not in our library10.1136/bjo.86.2.238

  49. 49.

    Fresco, P., Borges, F., Diniz, C., & Marques, M. P. (2006 ). New insights on the anticancer properties of dietary polyphenols. Medicinal Research Reviews, 26(6), 747–766.

    Not in our library10.1002/(issn)1098-1128

  50. 50.

    Frombaum, M., Le Clanche, S., Bonnefont‐Rousselot, D., & Borderie, D. (2012 ). Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and NO bioavailability: Potential benefits to cardiovascular diseases. Biochimie, 94(2), 269–276.

    Not in our library10.1016/j.biochi.2011.11.001

  51. 51.

    Gao, X., Xu, Y. X., Divine, G., Janakiraman, N., Chapman, R. A., & Gautam, S. C. (2002 ). Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. The Journal of Nutrition, 132(7), 2076–2081.

    Not in our library10.1093/jn/132.7.2076

  52. 52.

    Garvin, S., Öllinger, K., & Dabrosin, C. (2006 ). Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Letters, 231(1), 113–122.

    Not in our library10.1016/j.canlet.2005.01.031

  53. 53.

    Gasser, T. (2005 ). Genetics of Parkinson's disease. Current Opinion in Neurology, 18(4), 363–369.

    Not in our library10.1097/01.wco.0000170951.08924.3d

  54. 54.

    Giasson, B. I., Ischiropoulos, H., Lee, V. M.‐Y., & Trojanowski, J. Q. (2002 ). The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases 1, 2. Free Radical Biology and Medicine, 32(12), 1264–1275.

    Not in our library10.1016/s0891-5849(02)00804-3

  55. 55.

    Göçmen, A. Y., Burgucu, D., & Gümüşlü, S. (2011 ). Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40–CD40L system as a potential target. Applied Physiology, Nutrition, and Metabolism, 36(3), 323–330.

    Not in our library10.1139/h11-022

  56. 56.

    Goldberg, D. M., Yan, J., & Soleas, G. J. (2003 ). Absorption of three wine‐related polyphenols in three different matrices by healthy subjects. Clinical Biochemistry, 36(1), 79–87.

    Not in our library10.1016/s0009-9120(02)00397-1

  57. 57.

    Granzotto, A., & Zatta, P. (2011 ). Resveratrol acts not through anti‐aggregative pathways but mainly via its scavenging properties against Aβ and Aβ‐metal complexes toxicity. PLoS ONE, 6(6), e21565.

    Not in our library10.1371/journal.pone.0021565

  58. 58.

    Guo, R., Liu, B., Wang, K., Zhou, S., Li, W., & Xu, Y. (2014 ). Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF‐κB pathway. Diabetes and Vascular Disease Research, 11(2), 92–102.

    Not in our library10.1177/1479164113520332

  59. 59.

    Gurusamy, N., Ray, D., Lekli, I., & Das, D. K. (2010 ). Red wine antioxidant resveratrol‐modified cardiac stem cells regenerate infarcted myocardium. Journal of Cellular and Molecular Medicine, 14(9), 2235–2239.

    Not in our library10.1111/j.1582-4934.2010.01140.x

  60. 60.

    Gusman, J., Malonne, H., & Atassi, G. (2001 ). A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis, 22(8), 1111–1117.

    Not in our library10.1093/carcin/22.8.1111

  61. 61.

    Hamadi, N., Mansour, A., Hassan, M. H., Khalifi‐Touhami, F., & Badary, O. (2012 ). Ameliorative effects of resveratrol on liver injury in streptozotocin‐induced diabetic rats. Journal of Biochemical and Molecular Toxicology, 26(10), 384–392.

    Not in our library10.1002/jbt.21432

  62. 62.

    Harikumar, K. B., & Aggarwal, B. B. (2008 ). Resveratrol: A multitargeted agent for age‐associated chronic diseases. Cell Cycle, 7(8), 1020–1035.

    Not in our library10.4161/cc.7.8.5740

  63. 63.

    Heebøll, S., Thomsen, K. L., Clouston, A., Sundelin, E. I., Radko, Y., Christensen, L. P., … Grønbæk, H. (2015 ). Effect of resveratrol on experimental non‐alcoholic steatohepatitis. Pharmacological Research, 95, 34–41.

    Not in our library10.1016/j.phrs.2015.03.005

  64. 64.

    Hightower, K., & McCready, J. (1991 ). Effect of selenite on epithelium of cultured rabbit lens. Investigative Ophthalmology and Visual Science, 32(2), 406–409.

    Not in our library

  65. 65.

    Howe, G. R., Benito, E., Castelleto, R., Cornée, J., Estève, J., Gallagher, R. P., … Shu, Z. (1992 ). Dietary intake of fiber and decreased risk of cancers of the colon and rectum: Evidence from the combined analysis of 13 case‐control studies. Journal of the National Cancer Institute, 84(24), 1887–1896.

    Not in our library10.1093/jnci/84.24.1887

  66. 66.
  67. 67.

    Huang, C., Ma, W. Y., Goranson, A., & Dong, Z. (1999 ). Resveratrol suppresses cell transformation and induces apoptosis through a p53‐dependent pathway. Carcinogenesis, 20(2), 237–242.

    Not in our library10.1093/carcin/20.2.237

  68. 68.

    Hwang, D., & Lim, Y.‐H. (2015 ). Resveratrol antibacterial activity against Escherichia coli is mediated by Z‐ring formation inhibition via suppression of FtsZ expression. Scientific Reports, 5, 10029

    Not in our library10.1038/srep10029

  69. 69.

    Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., … Pezzuto, J. M. (1997 ). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275(5297), 218–220.

    Not in our library10.1126/science.275.5297.218

  70. 70.

    Jeon, B. T., Jeong, E. A., Shin, H. J., Lee, Y., Lee, D. H., Kim, H. J., … Roh, G. S. (2012 ). Resveratrol attenuates obesity‐associated peripheral and central inflammation and improves memory deficit in mice fed a high‐fat diet. Diabetes, 61(6), 1444–1454.

    Not in our library10.2337/db11-1498

  71. 71.

    Ji, G., Wang, Y., Deng, Y., Li, X., & Jiang, Z. (2015 ). Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline‐deficient diet‐induced steatohepatitis through regulating autophagy. Lipids in Health and Disease, 14(1), 134

    Not in our library10.1186/s12944-015-0139-6

  72. 72.

    Jiang, B., Guo, L., Li, B. Y., Zhen, J. H., Song, J., Peng, T., … Gao, H. Q. (2013 ). Resveratrol attenuates early diabetic nephropathy by down‐regulating glutathione s‐transferases Mu in diabetic rats. Journal of Medicinal Food, 16(6), 481–486.

    Not in our library10.1089/jmf.2012.2686

  73. 73.

    Johnson, W., Morrissey, R. L., Usborne, A. L., Kapetanovic, I., Crowell, J. A., Muzzio, M., & McCormick, D. L. (2011 ). Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food and Chemical Toxicology, 49(12), 3319–3327.

    Not in our library10.1016/j.fct.2011.08.023

  74. 74.

    Kalra, N., Roy, P., Prasad, S., & Shukla, Y. (2008 ). Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sciences, 82(7), 348–358.

    Not in our library10.1016/j.lfs.2007.11.006

  75. 75.

    Kashani, M. S., Tavirani, M. R., Talaei, S. A., & Salami, M. (2011 ). Aqueous extract of lavender (Lavandula angustifolia) improves the spatial performance of a rat model of Alzheimer's disease. Neuroscience bulletin, 27(2), 99–106.

    Not in our library10.1007/s12264-011-1149-7

  76. 76.

    Kawada, N., Seki, S., Inoue, M., & Kuroki, T. (1998 ). Effect of antioxidants, resveratrol, quercetin, and N‐acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology, 27(5), 1265–1274.

    Not in our library10.1002/(issn)1527-3350

  77. 77.

    Kedzierski, L., Curtis, J. M., Kaminska, M., Jodynis‐Liebert, J., & Murias, M. (2007 ). In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes. Parasitology Research, 102(1), 91–97.

    Not in our library10.1007/s00436-007-0729-y

  78. 78.

    Kim, J., Cha, Y.‐N., & Surh, Y.‐J. (2010 ). A protective role of nuclear factor‐erythroid 2‐related factor‐2 (Nrf2) in inflammatory disorders. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 690(1), 12–23.

    Not in our library10.1016/j.mrfmmm.2009.09.007

  79. 79.

    Kim, Y. H., Kim, Y. S., Roh, G. S., Choi, W. S., & Cho, G. J. (2012 ). Resveratrol blocks diabetes‐induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmologica, 90(1), e31–e37.

    Not in our library10.1111/j.1755-3768.2011.02243.x

  80. 80.

    Kim, Y.‐A., Rhee, S. H., Park, K. Y., & Choi, Y. H. (2003 ). Antiproliferative effect of resveratrol in human prostate carcinoma cells. Journal of Medicinal Food, 6(4), 273–280.

    Not in our library10.1089/109662003772519813

  81. 81.

    Kong, G. Y., Van Bergen, N. J., Trounce, I. A., & Crowston, J. G. (2009 ). Mitochondrial dysfunction and glaucoma. Journal of Glaucoma, 18(2), 93–100.

    Not in our library10.1097/ijg.0b013e318181284f

  82. 82.

    Koshimura, I., Imai, H., Hidano, T., Endo, K., Mochizuki, H., Kondo, T., & Mizuno, Y. (1997 ). Dimethoxyphenylethylamine and tetrahydropapaverine are toxic to the nigrostriatal system. Brain Research, 773(1), 108–116.

    Not in our library10.1016/s0006-8993(97)00922-0

  83. 83.

    Koushki, M., Dashatan, N. A., & Meshkani, R. (2018 ). Effect of resveratrol supplementation on inflammatory markers: A systematic review and meta‐analysis of randomized controlled trials. Clinical Therapeutics, 40, 1180–1192.e5.

    Not in our library10.1016/j.clinthera.2018.05.015

  84. 84.

    Ku, C. R., Lee, H. J., Kim, S. K., Lee, E. Y., Lee, M. K., & Lee, E. J. (2012 ). Resveratrol prevents streptozotocin‐induced diabetes by inhibiting the apoptosis of pancreatic β‐cell and the cleavage of poly (ADP‐ribose) polymerase. Endocrine Journal, 59(2), 103–109.

    Not in our library10.1507/endocrj.ej11-0194

  85. 85.

    Kucharczak, J., Simmons, M. J., Fan, Y., & Gélinas, C. (2003 ). To be, or not to be: NF‐κB is the answer–role of Rel/NF‐κB in the regulation of apoptosis. Oncogene, 22(56), 8961–8982.

    Not in our library10.1038/sj.onc.1207230

  86. 86.

    Kukreja, A., Wadhwa, N., & Tiwari, A. (2013 ). Therapeutic role of natural agents in beta‐thalassemia: A review. Journal of Pharmacy Research, 6(9), 954–959.

    Not in our library10.1016/j.jopr.2013.10.002

  87. 87.
  88. 88.

    Laslett, L. J., Alagona, P. Jr, Clark, B. A. 3rd, Drozda, J. P. Jr, Saldivar, F., Wilson, S. R., … Hart, M. (2012 ). The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the American College of Cardiology. Journal of the American College of Cardiology, 60(25_S), S1–S49.

    Not in our library10.1016/j.jacc.2012.11.002

  89. 89.

    la Porte, C., Voduc, N., Zhang, G., Seguin, I., Tardiff, D., Singhal, N., & Cameron, D. W. (2010 ). Steady‐state pharmacokinetics and tolerability of trans‐resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clinical Pharmacokinetics, 49(7), 449–454.

    Not in our library10.2165/11531820-000000000-00000

  90. 90.

    Lee, Y.‐E., Kim, J. W., Lee, E. M., Ahn, Y. B., Song, K. H., Yoon, K. H., … Ko, S. H. (2012 ). Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice. PLoS ONE, 7(11), e50412

    Not in our library10.1371/journal.pone.0050412

  91. 91.

    Leikert, J. F., Räthel, T. R., Wohlfart, P., Cheynier, V., Vollmar, A. M., & Dirsch, V. M. (2002 ). Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation, 106(13), 1614–1617.

    Not in our library10.1161/01.cir.0000034445.31543.43

  92. 92.

    Li, H., & Förstermann, U. (2000 ). Nitric oxide in the pathogenesis of vascular disease. The Journal of Pathology, 190(3), 244–254.

    Not in our library10.1002/(issn)1096-9896

  93. 93.

    Li, F., Gong, Q., Dong, H., & Shi, J. (2012 ). Resveratrol, a neuroprotective supplement for Alzheimer's disease. Current Pharmaceutical Design, 18(1), 27–33.

    Not in our library10.2174/138161212798919075

  94. 94.

    Li, L., Henry, G. E., & Seeram, N. P. (2009 ). Identification and bioactivities of resveratrol oligomers and flavonoids from Carex folliculata seeds. Journal of Agricultural and Food Chemistry, 57(16), 7282–7287.

    Not in our library10.1021/jf901716j

  95. 95.

    Li, C., Wang, L., Huang, K., & Zheng, L. (2012 ). Endoplasmic reticulum stress in retinal vascular degeneration: Protective role of resveratrol ER stress in retinal vascular degeneration. Investigative Ophthalmology and Visual Science, 53(6), 3241–3249.

    Not in our library10.1167/iovs.11-8406

  96. 96.

    Li, H., Wu, W. K., Zheng, Z., Che, C. T., Li, Z. J., Xu, D. D., … Wang, M. (2010 ). 3, 3′, 4, 5, 5′‐pentahydroxy‐trans‐stilbene, a resveratrol derivative, induces apoptosis in colorectal carcinoma cells via oxidative stress. European Journal of Pharmacology, 637(1), 55–61.

    Not in our library10.1016/j.ejphar.2010.04.009

  97. 97.

    Li, H., Xia, N., & Förstermann, U. (2012 ). Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide, 26(2), 102–110.

    Not in our library10.1016/j.niox.2011.12.006

  98. 98.

    Liang, J., Tian, S., Han, J., & Xiong, P. (2014 ). Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction. Renal Failure, 36(2), 285–291.

    Not in our library10.3109/0886022x.2013.844644

  99. 99.

    Lins, A. P., Ribeiro, M. N. D. S., Gottlieb, O. R., & Gottlieb, H. E. (1982 ). Gnetins: Resveratrol oligomers from Gnetum species. Journal of Natural Products, 45(6), 754–761.

    Not in our library10.1021/np50024a022

  100. 100.

    Liu, Y., Qin, L., Wilson, B. C., An, L., Hong, J. S., & Liu, B. (2002 ). Inhibition by naloxone stereoisomers of β‐amyloid peptide (1–42)‐induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. Journal of Pharmacology and Experimental Therapeutics, 302(3), 1212–1219.

    Not in our library10.1124/jpet.102.035956

  101. 101.

    Liu, X.‐Q., Wu, B. J., Pan, W. H., Zhang, X. M., Liu, J. H., Chen, M. M., … Chao, H. M. (2013 ). Resveratrol mitigates rat retinal ischemic injury: The roles of matrix metalloproteinase‐9, inducible nitric oxide, and heme oxygenase‐1. Journal of Ocular Pharmacology and Therapeutics, 29(1), 33–40.

    Not in our library10.1089/jop.2012.0141

  102. 102.

    Liu, G.‐S., Zhang, Z.‐S., Yang, B., & He, W. (2012 ). Resveratrol attenuates oxidative damage and ameliorates cognitive impairment in the brain of senescence‐accelerated mice. Life sciences, 91(17–18), 872–877.

    Not in our library10.1016/j.lfs.2012.08.033

  103. 103.

    Losso, J. N., Truax, R. E., & Richard, G. (2010 ). Trans‐resveratrol inhibits hyperglycemia‐induced inflammation and connexin downregulation in retinal pigment epithelial cells. Journal of Agricultural and Food Chemistry, 58(14), 8246–8252.

    Not in our library10.1021/jf1012067

  104. 104.

    Lu, C., Guo, Y., Yan, J., Luo, Z., Luo, H. B., Yan, M., … Li, X. (2013 ). Design, synthesis, and evaluation of multitarget‐directed resveratrol derivatives for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry, 56(14), 5843–5859.

    Not in our library10.1021/jm400567s

  105. 105.

    Luna, C., Li, G., Liton, P. B., Qiu, J., Epstein, D. L., Challa, P., & Gonzalez, P. (2009 ). Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food and Chemical Toxicology, 47(1), 198–204.

    Not in our library10.1016/j.fct.2008.10.029

  106. 106.

    Ma, T., Tan, M. S., Yu, J. T., & Tan, L. (2014 ). Resveratrol as a therapeutic agent for Alzheimer's disease. BioMed Research International, 2014, 350516.

    Not in our library10.1155/2014/350516

  107. 107.

    Mahyar‐Roemer, M., Katsen, A., Mestres, P., & Roemer, K. (2001 ). Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. International Journal of Cancer, 94(5), 615–622.

    Not in our library10.1002/(issn)1097-0215

  108. 108.

    McCarthy, S. A., Symonds, H. S., & Van Dyke, T. (1994 ). Regulation of apoptosis in transgenic mice by simian virus 40 T antigen‐mediated inactivation of p53. Proceedings of the National Academy of Sciences, 91(9), 3979–3983.

    Not in our library10.1073/pnas.91.9.3979

  109. 109.

    Miller, R. L., Sun, G. Y., & Sun, A. Y. (2007 ). Cytotoxicity of paraquat in microglial cells: involvement of PKCδ‐and ERK1/2‐dependent NADPH oxidase. Brain Research, 1167, 129–139.

    Not in our library10.1016/j.brainres.2007.06.046

  110. 110.

    Mukhopadhyay, P., Pacher, P., & Das, D. K. (2011 ). MicroRNA signatures of resveratrol in the ischemic heart. Annals of the New York Academy of Sciences, 1215(1), 109–116.

    Not in our library10.1111/j.1749-6632.2010.05866.x

  111. 111.

    Murakami, A., Matsumoto, K., Koshimizu, K., & Ohigashi, H. (2003 ). Effects of selected food factors with chemopreventive properties on combined lipopolysaccharide‐and interferon‐γ‐induced IκB degradation in RAW264. 7 macrophages. Cancer Letters, 195(1), 17–25.

    Not in our library10.1016/s0304-3835(03)00058-2

  112. 112.

    Murano, A., Morinaga, N., Iwamaru, Y., Yahiro, K., Tagashira, M., Moss, J., … Noda, M. (2005 ). Acidic conditions enhance bactericidal effects of sodium bisulfite on Helicobacter pylori. Helicobacter, 10(2), 132–135.

    Not in our library10.1111/j.1523-5378.2005.00299.x

  113. 113.

    Nakagawa, H., Kiyozuka, Y., Uemura, Y., Senzaki, H., Shikata, N., Hioki, K., & Tsubura, A. (2001 ). Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. Journal of Cancer Research and Clinical Oncology, 127(4), 258–264.

    Not in our library10.1007/s004320000190

  114. 114.

    Nakamura, M., Saito, H., Ikeda, M., Hokari, R., Kato, N., Hibi, T., & Miura, S. (2010 ). An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World Journal of Gastroenterology, 16(2), 184–192.

    Not in our library10.3748/wjg.v16.i2.184

  115. 115.

    Nunes, T., Almeida, L., Rocha, J. F., Falcão, A., Fernandes‐Lopes, C., Loureiro, A. I., … Soares‐da‐Silva, P. (2009 ). Pharmacokinetics of trans‐resveratrol following repeated administration in healthy elderly and young subjects. The Journal of Clinical Pharmacology, 49(12), 1477–1482.

    Not in our library10.1177/0091270009339191

  116. 116.

    Palamara, A. T., Nencioni, L., Aquilano, K., De Chiara, G., Hernandez, L., Cozzolino, F., … Garaci, E. (2005 ). Inhibition of influenza A virus replication by resveratrol. Journal of Infectious Diseases, 191(10), 1719–1729.

    Not in our library10.1086/429694

  117. 117.

    Palermo, A., Maggi, D., Maurizi, A. R., Pozzilli, P., & Buzzetti, R. (2014 ). Prevention of type 2 diabetes mellitus: Is it feasible? Diabetes/Metabolism Research and Reviews, 30(S1), 4–12.

    Not in our library10.1002/dmrr.2513

  118. 118.

    Palsamy, P., & Subramanian, S. (2010 ). Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic β‐cell dysfunction in streptozotocin‐nicotinamide‐induced diabetic rats. Journal of Cellular Physiology, 224(2), 423–432.

    Not in our library10.1002/jcp.22138

  119. 119.

    Palsamy, P., & Subramanian, S. (2011 ). Resveratrol protects diabetic kidney by attenuating hyperglycemia‐mediated oxidative stress and renal inflammatory cytokines via Nrf2–Keap1 signaling. Biochimica et Biophysica Acta (BBA)‐Molecular Basis of Disease, 1812(7), 719–731.

    Not in our library10.1016/j.bbadis.2011.03.008

  120. 120.

    Parekh, P., Motiwale, L., Naik, N., & Rao, K. V. (2011 ). Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Experimental and Toxicologic Pathology, 63(1), 167–173.

    Not in our library10.1016/j.etp.2009.11.005

  121. 121.

    Park, S. Y., Jeong, K. J., Lee, J., Yoon, D. S., Choi, W. S., Kim, Y. K., … Lee, H. Y. (2007 ). Hypoxia enhances LPA‐induced HIF‐1α and VEGF expression: Their inhibition by resveratrol. Cancer Letters, 258(1), 63–69.

    Not in our library10.1016/j.canlet.2007.08.011

  122. 122.

    Passos, C. L., Ferreira, C., Soares, D. C., & Saraiva, E. M. (2015 ). Leishmanicidal effect of synthetic trans‐resveratrol analogs. PLoS ONE, 10(10), e0141778

    Not in our library10.1371/journal.pone.0141778

  123. 123.

    Patel, K. R., Brown, V. A., Jones, D. J., Britton, R. G., Hemingway, D., Miller, A. S., … Brown, K. (2010 ). Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Research, 70(19), 7392–7399.

    Not in our library10.1158/0008-5472.can-10-2027

  124. 124.

    Pervaiz, S. (2003 ). Resveratrol: From grapevines to mammalian biology. The FASEB Journal, 17(14), 1975–1985.

    Not in our library10.1096/fj.03-0168rev

  125. 125.

    Pirhan, D., Yüksel, N., Emre, E., Cengiz, A., & Kürşat Yıldız, D. (2016 ). Riluzole‐and resveratrol‐induced delay of retinal ganglion cell death in an experimental model of glaucoma. Current Eye Research, 41(1), 59–69.

    Not in our library10.3109/02713683.2015.1004719

  126. 126.

    Porquet, D., Casadesús, G., Bayod, S., Vicente, A., Canudas, A. M., Vilaplana, J., … Pallàs, M. (2013 ). Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age, 35(5), 1851–1865.

    Not in our library10.1007/s11357-012-9489-4

  127. 127.

    Rahvar, M., Nikseresht, M., Shafiee, S. M., Naghibalhossaini, F., Rasti, M., Panjehshahin, M. R., … Owji, A. A. (2011 ). Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain. Neurochemical Research, 36(5), 761–765.

    Not in our library10.1007/s11064-010-0396-8

  128. 128.

    Raj, P., Louis, X. L., Thandapilly, S. J., Movahed, A., Zieroth, S., & Netticadan, T. (2014 ). Potential of resveratrol in the treatment of heart failure. Life Sciences, 95(2), 63–71.

    Not in our library10.1016/j.lfs.2013.12.011

  129. 129.

    Razali, N., Agarwal, R., Agarwal, P., Kumar, S., Tripathy, M., Vasudevan, S., … Ismail, N. M. (2015 ). Role of adenosine receptors in resveratrol‐induced intraocular pressure lowering in rats with steroid‐induced ocular hypertension. Clinical and Experimental Ophthalmology, 43(1), 54–66.

    Not in our library10.1111/ceo.12375

  130. 130.

    Reagan‐Shaw, S., Afaq, F., Aziz, M. H., & Ahmad, N. (2004 ). Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B‐mediated responses by resveratrol in SKH‐1 hairless mouse skin. Oncogene, 23(30), 5151–5160.

    Not in our library10.1038/sj.onc.1207666

  131. 131.

    Regitz, C., Fitzenberger, E., Mahn, F. L., Dußling, L. M., & Wenzel, U. (2016 ). Resveratrol reduces amyloid‐beta (Aβ 1–42)‐induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans. European Journal of Nutrition, 55(2), 741–747.

    Not in our library10.1007/s00394-015-0894-1

  132. 132.

    Rivera, L., Morón, R., Zarzuelo, A., & Galisteo, M. (2009 ). Long‐term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochemical Pharmacology, 77(6), 1053–1063.

    Not in our library10.1016/j.bcp.2008.11.027

  133. 133.

    Rivière, C., Papastamoulis, Y., Fortin, P. Y., Delchier, N., Andriamanarivo, S., Waffo‐Teguo, P., … Monti, J. P. (2010 ). New stilbene dimers against amyloid fibril formation. Bioorganic and Medicinal Chemistry Letters, 20(11), 3441–3443.

    Not in our library10.1016/j.bmcl.2009.09.074

  134. 134.

    Roberson, E. D., & Mucke, L. (2006 ). 100 years and counting: Prospects for defeating Alzheimer's disease. Science, 314(5800), 781–784.

    Not in our library10.1126/science.1132813

  135. 135.

    Romano, A. D., Serviddio, G., de Matthaeis, A., Bellanti, F., & Vendemiale, G. (2009 ). Oxidative stress and aging. Journal of Nephrology, 23, S29–S36.

    Not in our library

  136. 136.

    Rotches‐Ribalta, M., Andres‐Lacueva, C., Estruch, R., Escribano, E., & Urpi‐Sarda, M. (2012 ). Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacological Research, 66(5), 375–382.

    Not in our library10.1016/j.phrs.2012.08.001

  137. 137.

    Sadeghi, A., Seyyed Ebrahimi, S. S., Golestani, A., & Meshkani, R. (2017 ). Resveratrol ameliorates palmitate‐induced inflammation in skeletal muscle cells by attenuating oxidative stress and JNK/NF‐κB pathway in a SIRT1‐Independent mechanism. Journal of cellular biochemistry, 118(9), 2654–2663.

    Not in our library10.1002/jcb.25868

  138. 138.

    Saiko, P., Szakmary, A., Jaeger, W., & Szekeres, T. (2008 ). Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutation Research/Reviews in Mutation Research, 658(1), 68–94.

    Not in our library10.1016/j.mrrev.2007.08.004

  139. 139.

    Saldanha, J. F., Leal Vde, O., Stenvinkel, P., Carraro‐Eduardo, J. C., & Mafra, D. (2013 ). Resveratrol: Why is it a promising therapy for chronic kidney disease patients? Oxidative Medicine and Cellular Longevity, 2013, 963217.

    Not in our library10.1155/2013/963217

  140. 140.

    Sanders, T. H., McMichael, R. W., & Hendrix, K. W. (2000 ). Occurrence of resveratrol in edible peanuts. Journal of Agricultural and Food Chemistry, 48(4), 1243–1246.

    Not in our library10.1021/jf990737b

  141. 141.

    Savouret, J. F., & Quesne, M. (2002 ). Resveratrol and cancer: A review. Biomedicine and Pharmacotherapy, 56(2), 84–87.

    Not in our library10.1016/s0753-3322(01)00158-5

  142. 142.

    Selkoe, D. J. (2001 ). Alzheimer's disease: Genes, proteins, and therapy. Physiological Reviews, 81(2), 741–766.

    Not in our library10.1152/physrev.2001.81.2.741

  143. 143.

    Shanaki, M., Hossein‐Nezhad, A., Meshkani, R., Beigy, M., Shirzad, M., Pasalar, P., … Golmohammadi, T. (2016 ). Effects of resveratrol on crosstalk between canonical Β‐catenin/Wnt and FOXO pathways in coronary artery disease patients with metabolic syndrome: A case control study. Iranian Journal of Pharmaceutical Research: IJPR, 15(3), 547.

    Not in our library

  144. 144.

    She, Q.‐B., Bode, A. M., Ma, W. Y., Chen, N. Y., & Dong, Z. (2001 ). Resveratrol‐induced activation of p53 and apoptosis is mediated by extracellular‐signal‐regulated protein kinases and p38 kinase. Cancer Research, 61(4), 1604–1610.

    Not in our library

  145. 145.

    Shishodia, S., & Aggarwal, B. B. (2006 ). Resveratrol: A polyphenol for all seasons. Oxidative Stress and Disease, 20, 1.

    Not in our library

  146. 146.

    Silan, C. (2008 ). The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin‐induced diabetic rats. Biological and Pharmaceutical Bulletin, 31(5), 897–902.

    Not in our library10.1248/bpb.31.897

  147. 147.

    Society, A.C (2007 ). Breast cancer facts & figures. Atlanta, GA: American Cancer Society.

    Not in our library

  148. 148.

    Soheili, M., Tavirani, M. R., & Salami, M. (2015 ). Lavandula angustifolia extract improves deteriorated synaptic plasticity in an animal model of Alzheimer's disease. Iranian Journal of Basic Medical Sciences, 18(11), 1147.

    Not in our library

  149. 149.

    Soufi, F. G., Mohammad‐Nejad, D., & Ahmadieh, H. (2012 ). Resveratrol improves diabetic retinopathy possibly through oxidative stress–nuclear factor κB–apoptosis pathway. Pharmacological Reports, 64(6), 1505–1514.

    Not in our library10.1016/s1734-1140(12)70948-9

  150. 150.

    Spanier, G., Xu, H., Xia, N., Tobias, S., Deng, S., Wojnowski, L., … Li, H. (2009 ). Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). Journal of Physiology and Pharmacology, 60(Suppl 4), 111–116.

    Not in our library

  151. 151.

    Stenvinkel, P. (2010 ). Inflammation as a target for improving health in chronic kidney disease. F1000 Medicine Reports, 2, 88.

    Not in our library10.3410/m2-88

  152. 152.

    Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., … Dannenberg, A. J. (1998 ). Resveratrol inhibits cyclooxygenase‐2 transcription and activity in phorbol ester‐treated human mammary epithelial cells. Journal of Biological Chemistry, 273(34), 21875–21882.

    Not in our library10.1074/jbc.273.34.21875

  153. 153.

    Sun, A. Y., Wang, Q., Simonyi, A., & Sun, G. Y. (2008 ). Botanical phenolics and brain health. Neuromolecular Medicine, 10(4), 259–274.

    Not in our library10.1007/s12017-008-8052-z

  154. 154.

    Sun, A. Y., Wang, Q., Simonyi, A., & Sun, G. Y. (2010 ). Resveratrol as a therapeutic agent for neurodegenerative diseases. Molecular Neurobiology, 41(2–3), 375–383.

    Not in our library10.1007/s12035-010-8111-y

  155. 155.

    Sun, A., Yang, W., & Kim, H. (1993 ). Free radical and lipid peroxidation in manganese‐induced neuronal cell injury. Annals of the New York Academy of Sciences, 679(1), 358–363.

    Not in our library10.1111/j.1749-6632.1993.tb18322.x

  156. 156.

    Swenson‐Fields, K. I., Vivian, C. J., Salah, S. M., Peda, J. D., Davis, B. M., van Rooijen, N., … Fields, T. A. (2013 ). Macrophages promote polycystic kidney disease progression. Kidney International, 83(5), 855–864.

    Not in our library10.1038/ki.2012.446

  157. 157.

    Szkudelski, T., & Szkudelska, K. (2015 ). Resveratrol and diabetes: From animal to human studies. Biochimica et Biophysica Acta (BBA)‐Molecular Basis of Disease, 1852(6), 1145–1154.

    Not in our library10.1016/j.bbadis.2014.10.013

  158. 158.

    Ta, M. H., Harris, D. C., & Rangan, G. K. (2013 ). Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology (Carlton), 18(5), 317–330.

    Not in our library10.1111/nep.12045

  159. 159.

    Tezel, G. (2006 ). Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences. Progress in Retinal and Eye Research, 25(5), 490–513.

    Not in our library10.1016/j.preteyeres.2006.07.003

  160. 160.

    Veras, P. S. T., & Bezerra de Menezes, J. P. (2016 ). Using proteomics to understand how Leishmania parasites survive inside the host and establish infection. International Journal of Molecular Sciences, 17(8), 1270

    Not in our library10.3390/ijms17081270

  161. 161.

    Walle, T. (2011 ). Bioavailability of resveratrol. Annals of the New York Academy of Sciences, 1215(1), 9–15.

    Not in our library10.1111/j.1749-6632.2010.05842.x

  162. 162.

    Wang, Y., Romigh, T., He, X., Orloff, M. S., Silverman, R. H., Heston, W. D., & Eng, C. (2010 ). Resveratrol regulates the PTEN/AKT pathway through androgen receptor‐dependent and‐independent mechanisms in prostate cancer cell lines. Human Molecular Genetics, 19, 4319–4329.

    Not in our library10.1093/hmg/ddq354

  163. 163.

    Wenzel, E., Soldo, T., Erbersdobler, H., & Somoza, V. (2005 ). Bioactivity and metabolism of trans‐resveratrol orally administered to Wistar rats. Molecular Nutrition and Food Research, 49(5), 482–494.

    Not in our library10.1002/(issn)1613-4133

  164. 164.

    Westerheide, S. (2013 ). Stress‐inducible regulation of heat shock factor 1 by the deacetylase SIRT1 (vol 323, pg 1063, 2009). Science, 342(6161), 931.

    Not in our library10.1126/science.1165946

  165. 165.

    Wilson, P. D., & Goilav, B. (2007 ). Cystic disease of the kidney. Annual Review of Pathology Mechanisms of Disease, 2, 341–368.

    Not in our library10.1146/annurev.pathol.2.010506.091850

  166. 166.

    Witztum, J. L., & Steinberg, D. (1991 ). Role of oxidized low density lipoprotein in atherogenesis. Journal of Clinical Investigation, 88(6), 1785

    Not in our library10.1172/jci115499

  167. 167.

    Wu, M., Gu, J., Mei, S., Xu, D., Jing, Y., Yao, Q., … Mei, C. (2016 ). Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB‐induced inflammation. Nephrology Dialysis Transplantation, 31, 1826–1834.

    Not in our library10.1093/ndt/gfw058

  168. 168.

    Wu, Y., & Liu, F. (2013 ). Targeting mTOR: Evaluating the therapeutic potential of resveratrol for cancer treatment. Anti‐Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry‐Anti‐Cancer Agents), 13(7), 1032–1038.

    Not in our library10.2174/18715206113139990113

  169. 169.

    Xuan, W., Wu, B., Chen, C., Chen, B., Zhang, W., Xu, D., … Liao, Y. (2012 ). Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine. Critical Care Medicine, 40(11), 3026–3033.

    Not in our library10.1097/ccm.0b013e31825fd7da

  170. 170.

    Yang, T., Li, S., Zhang, X., Pang, X., Lin, Q., & Cao, J. (2015 ). Resveratrol, sirtuins, and viruses. Reviews in Medical Virology, 25(6), 431–445.

    Not in our library10.1002/rmv.1858

  171. 171.

    Yar, A. S., Menevse, S., Dogan, I., Alp, E., Ergin, V., Cumaoglu, A., … Menevse, A. (2012 ). Investigation of ocular neovascularization–related genes and oxidative stress in diabetic rat eye tissues after resveratrol treatment. Journal of Medicinal Food, 15(4), 391–398.

    Not in our library10.1089/jmf.2011.0135

  172. 172.

    Yashiro, T., Nanmoku, M., Shimizu, M., Inoue, J., & Sato, R. (2012 ). Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element‐binding proteins. Atherosclerosis, 220(2), 369–374.

    Not in our library10.1016/j.atherosclerosis.2011.11.006

  173. 173.

    Yiu, C.‐Y., Chen, S. Y., Chang, L. K., Chiu, Y. F., & Lin, T. P. (2010 ). Inhibitory effects of resveratrol on the Epstein‐Barr virus lytic cycle. Molecules, 15(10), 7115–7124.

    Not in our library10.3390/molecules15107115

  174. 174.

    Zain, W. Z. W. M., Ahmat, N., Norizan, N. H., & Nazri, N. A. A. M. (2011 ). The evaluation of antioxidant, antibacterial and structural identification activity of trimer resveratrol from Malaysia's Dipterocarpaceae. Australian Journal of Basic and Applied Sciences, 5(5), 926–929.

    Not in our library

  175. 175.

    Zhang, Q., Tang, X., Lu, Q. Y., Zhang, Z. F., Brown, J., & Le, A. D. (2005 ). Resveratrol inhibits hypoxia‐induced accumulation of hypoxia‐inducible factor‐1α and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Molecular Cancer Therapeutics, 4(10), 1465–1474.

    Not in our library10.1158/1535-7163.mct-05-0198

  176. 176.

    Zhou, H.‐B., Chen, J. J., Wang, W. X., Cai, J. T., & Du, Q. (2005 ). Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World Journal of Gastroenterology, 11(2), 280–284.

    Not in our library10.3748/wjg.v11.i2.280

  177. 177.

    Zoja, C., Corna, D., Locatelli, M., Rottoli, D., Pezzotta, A., Morigi, M., … Remuzzi, G. (2014 ). Effects of MCP‐1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. Nephron, 129(1), 52–61.

    Not in our library10.1159/000369149

  178. 178.

    Zordoky, B. N., Robertson, I. M., & Dyck, J. R. (2015 ). Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochimica et Biophysica Acta (BBA)‐Molecular Basis of Disease, 1852(6), 1155–1177.

    Not in our library10.1016/j.bbadis.2014.10.016

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.